MDB Capital Holdings
  • About
    • About Us
    • Team
    • Holistic Model
  • Criteria
  • Process
  • Community
  • Companies
  • Investors
    • Press Releases
  • Submit Your Big Idea
Select Page

Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

by Tony Dammicci | Mar 15, 2023 | Press Releases

Paris and  Red Bank, N.J. March  13, 2023 Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under...

MDB Capital Holdings Announces Third MDB-Launched Company to Achieve FDA Approval

by Jim Foley | Nov 29, 2022 | Press Releases

DALLAS, T.X. / ACCESSWIRE / November 29, 2022 / MDB Capital Holdings, LLC, a privately-held public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today announced that...

Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)

by Jim Foley | Nov 17, 2022 | Press Releases

DALLAS, TX / ACCESSWIRE / November 17, 2022 / Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, completed its first financing as a broker-dealer for Cue Biopharma, Inc. (NASDAQ:CUE). The Public Ventures’ portion of the financing was...

MDB Capital Holdings Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq

by Jim Foley | Nov 11, 2022 | Press Releases

DALLAS, TX / ACCESSWIRE / November 11, 2022 / MDB Capital Holdings, LLC (“MDB”), a privately-held public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today...

Lou Basenese Joins MDB Capital Holdings as President and Chief Market Strategist

by Tyler Teske | Oct 6, 2022 | Press Releases

DALLAS, TX / ACCESSWIRE / October 6, 2022 / MDB Capital Holdings, LLC, a privately held Public Venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today announced the...

MDB Capital Holdings Hires Tony Dammicci as Chief Experience Officer

by Jim Foley | Oct 3, 2022 | Press Releases

DALLAS, TX / ACCESSWIRE / October 3, 2022 / MDB Capital Holdings, LLC, a privately held Public Venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today announced the...
« Older Entries

Recent Posts

  • Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
  • MDB Capital Holdings Announces Third MDB-Launched Company to Achieve FDA Approval
  • Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
  • MDB Capital Holdings Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
  • Lou Basenese Joins MDB Capital Holdings as President and Chief Market Strategist

Recent Comments

    Archives

    • March 2023
    • November 2022
    • October 2022
    • August 2022
    • July 2022
    • June 2022

    Categories

    • Press Releases
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    AboutCriteriaProcessCommunityCompaniesTeamInvestorsContact

    Governance   Terms of Use   Business Continuity
    © 2023 MDB Capital Holdings